The University of Pennsylvania School of Nursing
Ultima Vez Modificado: 13 de diciembre del 2011
Please comment on the Finnish protocol of giving 9 weekly administrations of Herceptin versus the 18 - three-weekly administrations that are currently done in the US.
Kevin Fox, MD, Medical Oncologist at Penn , responds:
The Finnish protocol treated a very small number of women, I believe fewer than 200. All of the other studies treated close to 10000 women with one year of herceptin. Although interesting, the weight of current evidence still favors a year of herceptin due to a larger sample of patients. Studies are being done to evaluate shorter courses of herceptin, but one year of treatment must still be considered standard.
This question and answer was part of the OncoLink Brown Bag Chat. Series, View the Life After Breast Cancer transcript.
Jun 16, 2011 - The U.S. Food and Drug Administration has approved the Inform Dual ISH test, a genetic test to determine whether women with breast cancer are human epidermal growth factor receptor 2-positive and therefore candidates for trastuzumab (Herceptin).
Jun 16, 2011
Mar 18, 2010
Dec 21, 2014